Aarti Drugs Limited (AARTIDRUGS.BO)
INR 431.25
(-0.45%)
INR 431.25
(-0.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 25.28 Billion INR | -6.9% |
| 2022 | 27.16 Billion INR | 9.14% |
| 2021 | 24.88 Billion INR | 15.49% |
| 2020 | 21.54 Billion INR | 19.31% |
| 2019 | 18.06 Billion INR | 15.71% |
| 2018 | 15.6 Billion INR | 25.52% |
| 2017 | 12.43 Billion INR | 4.05% |
| 2016 | 11.95 Billion INR | 5.31% |
| 2015 | 11.34 Billion INR | 3.71% |
| 2014 | 10.94 Billion INR | 12.82% |
| 2013 | 9.69 Billion INR | 17.59% |
| 2012 | 8.24 Billion INR | 25.12% |
| 2011 | 6.59 Billion INR | 31.58% |
| 2010 | 5.01 Billion INR | 4.71% |
| 2009 | 4.78 Billion INR | 25.22% |
| 2008 | 3.82 Billion INR | 22.33% |
| 2007 | 3.12 Billion INR | 7.9% |
| 2006 | 2.89 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.98 Billion INR | 7.74% |
| 2024 Q1 | 5.55 Billion INR | -10.43% |
| 2023 Q4 | 6.19 Billion INR | 2.32% |
| 2023 Q2 | 6.41 Billion INR | -2.96% |
| 2023 FY | 25.28 Billion INR | -6.9% |
| 2023 Q1 | 6.61 Billion INR | -10.95% |
| 2023 Q3 | 6.05 Billion INR | -5.55% |
| 2022 FY | 27.16 Billion INR | 9.14% |
| 2022 Q4 | 7.42 Billion INR | 11.82% |
| 2022 Q2 | 6.87 Billion INR | 10.57% |
| 2022 Q1 | 6.21 Billion INR | -10.41% |
| 2022 Q3 | 6.63 Billion INR | -3.45% |
| 2021 FY | 24.88 Billion INR | 15.49% |
| 2021 Q4 | 6.94 Billion INR | 9.37% |
| 2021 Q3 | 6.34 Billion INR | 9.52% |
| 2021 Q1 | 5.79 Billion INR | 15.59% |
| 2021 Q2 | 5.79 Billion INR | -0.06% |
| 2020 Q4 | 5.01 Billion INR | -5.37% |
| 2020 Q1 | 5.44 Billion INR | 21.14% |
| 2020 Q2 | 5.78 Billion INR | 6.14% |
| 2020 Q3 | 5.3 Billion INR | -8.28% |
| 2020 FY | 21.54 Billion INR | 19.31% |
| 2019 Q3 | 4.73 Billion INR | -0.84% |
| 2019 Q4 | 4.49 Billion INR | -5.04% |
| 2019 FY | 18.06 Billion INR | 15.71% |
| 2019 Q2 | 4.77 Billion INR | 17.78% |
| 2019 Q1 | 4.05 Billion INR | -11.7% |
| 2018 FY | 15.6 Billion INR | 25.52% |
| 2018 Q3 | 3.8 Billion INR | 9.41% |
| 2018 Q1 | 3.74 Billion INR | 13.18% |
| 2018 Q4 | 4.59 Billion INR | 20.79% |
| 2018 Q2 | 3.47 Billion INR | -7.18% |
| 2017 FY | 12.43 Billion INR | 4.05% |
| 2017 Q4 | 3.3 Billion INR | -1.41% |
| 2017 Q3 | 3.35 Billion INR | 5.06% |
| 2017 Q2 | 3.19 Billion INR | 23.62% |
| 2017 Q1 | 2.58 Billion INR | -13.6% |
| 2016 Q1 | 2.91 Billion INR | -7.16% |
| 2016 Q4 | 2.98 Billion INR | 3.19% |
| 2016 FY | 11.95 Billion INR | 5.31% |
| 2016 Q2 | 3.15 Billion INR | 8.1% |
| 2016 Q3 | 2.89 Billion INR | -8.08% |
| 2015 Q2 | 2.72 Billion INR | 3.55% |
| 2015 Q4 | 3.13 Billion INR | 18.48% |
| 2015 Q3 | 2.65 Billion INR | -2.8% |
| 2015 Q1 | 2.63 Billion INR | -8.96% |
| 2015 FY | 11.34 Billion INR | 3.71% |
| 2014 Q2 | 2.85 Billion INR | 10.12% |
| 2014 Q4 | 2.89 Billion INR | 11.42% |
| 2014 FY | 10.94 Billion INR | 12.82% |
| 2014 Q3 | 2.59 Billion INR | -9.2% |
| 2014 Q1 | 2.59 Billion INR | -7.88% |
| 2013 Q2 | 2.47 Billion INR | 13.36% |
| 2013 Q3 | 2.21 Billion INR | -10.51% |
| 2013 Q4 | 2.81 Billion INR | 27.07% |
| 2013 FY | 9.69 Billion INR | 17.59% |
| 2013 Q1 | 2.18 Billion INR | -0.72% |
| 2012 FY | 8.24 Billion INR | 25.12% |
| 2012 Q1 | 1.89 Billion INR | 0.0% |
| 2012 Q2 | 2.16 Billion INR | 13.91% |
| 2012 Q3 | 1.98 Billion INR | -8.25% |
| 2012 Q4 | 2.2 Billion INR | 10.93% |
| 2011 FY | 6.59 Billion INR | 31.58% |
| 2010 FY | 5.01 Billion INR | 4.71% |
| 2009 FY | 4.78 Billion INR | 25.22% |
| 2008 FY | 3.82 Billion INR | 22.33% |
| 2007 FY | 3.12 Billion INR | 7.9% |
| 2006 FY | 2.89 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 39.92% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -500.283% |
| Sigachi Industries Limited | 3.98 Billion INR | -533.798% |
| Bal Pharma Limited | 3.39 Billion INR | -645.41% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -97.406% |
| Medico Remedies Limited | 1.44 Billion INR | -1644.8% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -2323.517% |
| Venus Remedies Limited | 5.91 Billion INR | -327.522% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -3247.1% |
| Alpa Laboratories Limited | 1.08 Billion INR | -2225.363% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -50.145% |
| Shilpa Medicare Limited | 11.51 Billion INR | -119.57% |
| Lupin Limited | 200.1 Billion INR | 87.364% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 91.191% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 86.707% |
| Windlas Biotech Limited | 6.3 Billion INR | -300.753% |
| Suven Life Sciences Limited | 116.92 Million INR | -21524.887% |
| Eris Lifesciences Limited | 20.09 Billion INR | -25.853% |
| Valiant Laboratories Limited | 1.82 Billion INR | -1288.891% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 27.427% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -104.183% |
| Ipca Laboratories Limited | 76.22 Billion INR | 66.827% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -228.282% |
| Achyut Healthcare Limited | 61.36 Million INR | -41102.829% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 94.786% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -434.111% |
| RPG Life Sciences Limited | 5.82 Billion INR | -334.426% |
| Mankind Pharma Limited | 103.34 Billion INR | 75.533% |
| Laurus Labs Limited | 50.01 Billion INR | 49.447% |
| Piramal Pharma Limited | 81.71 Billion INR | 69.055% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -875.365% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 76.158% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 58.63% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 78.595% |
| Unichem Laboratories Limited | 16.57 Billion INR | -52.561% |
| Sequent Scientific Limited | 13.69 Billion INR | -84.604% |
| Novartis India Limited | 3.35 Billion INR | -654.641% |
| Wanbury Limited | 5.75 Billion INR | -339.256% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -140.507% |
| Wockhardt Limited | 27.89 Billion INR | 9.338% |
| Themis Medicare Limited | 3.81 Billion INR | -562.346% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -1111.573% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 62.276% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -10.746% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 90.942% |
| Divi's Laboratories Limited | 78.45 Billion INR | 67.768% |
| NATCO Pharma Limited | 40.02 Billion INR | 36.817% |
| Gufic Biosciences Limited | 8.06 Billion INR | -213.46% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -19.331% |
| Ind-Swift Limited | 5.02 Billion INR | -403.231% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -119.636% |
| FDC Limited | 19.42 Billion INR | -30.142% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -4914.877% |
| Granules India Limited | 45.06 Billion INR | 43.889% |
| Medicamen Biotech Limited | 1.79 Billion INR | -1310.2% |
| Alkem Laboratories Limited | 126.67 Billion INR | 80.039% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -95.177% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -6215.867% |
| Brooks Laboratories Limited | 794.86 Million INR | -3081.155% |
| Megasoft Limited | 373.95 Million INR | -6661.749% |
| ZIM Laboratories Limited | 3.67 Billion INR | -588.19% |
| Strides Pharma Science Limited | 40.51 Billion INR | 37.583% |
| Neuland Laboratories Limited | 15.58 Billion INR | -62.236% |
| Morepen Laboratories Limited | 17.01 Billion INR | -48.574% |
| Hikal Limited | 17.84 Billion INR | -41.689% |
| Indoco Remedies Limited | 17.89 Billion INR | -41.305% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -39.277% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1537.971% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -586.004% |
| Hester Biosciences Limited | 3.04 Billion INR | -730.277% |